Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

Gregory A. Wiseman, Thomas Elmer Witzig

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Aim: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%. This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with 90Y ibritumomab tiuxetan treatment. Materials and Methods: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed. Time to progression (TTP) of ≥12 months was noted in 78 patients (37%), who were identified as long-term responders and were further characterized. Results: Median age of the long-term responders was 58 years (range, 24-80 years) with 44% over 60 years, and 55% were male. Notably, 59% of patients had received ≥2 prior regimens, 33% had received ≥3 prior regimens, and 37% had failed to respond to immediate prior therapy. Median response duration was 28.1 months (range, 10.5-80.3+ months). Median TTP was 29.3 months (range, 12.1-81.5+ months). In patients with ongoing response, median TTP was 53.9 months (range, 49-82+ months). Conclusions: 90Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Failure to respond to prior therapy does not preclude achieving a long-term response with 90Y ibritumomab tiuxetan.

Original languageEnglish (US)
Pages (from-to)185-188
Number of pages4
JournalCancer Biotherapy and Radiopharmaceuticals
Volume20
Issue number2
DOIs
StatePublished - 2005

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Radioimmunotherapy
Therapeutics
Medical Records
ibritumomab tiuxetan

Keywords

  • Durable responses
  • Non-Hodgkin's lymphoma
  • Time to progression
  • Yttrium-90 ibritumomab tiuxetan

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

@article{c6da3ce42bb84c338f87427a32e45af7,
title = "Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin{\circledR}) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma",
abstract = "Aim: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin{\circledR}) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74{\%} to 82{\%}. This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with 90Y ibritumomab tiuxetan treatment. Materials and Methods: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed. Time to progression (TTP) of ≥12 months was noted in 78 patients (37{\%}), who were identified as long-term responders and were further characterized. Results: Median age of the long-term responders was 58 years (range, 24-80 years) with 44{\%} over 60 years, and 55{\%} were male. Notably, 59{\%} of patients had received ≥2 prior regimens, 33{\%} had received ≥3 prior regimens, and 37{\%} had failed to respond to immediate prior therapy. Median response duration was 28.1 months (range, 10.5-80.3+ months). Median TTP was 29.3 months (range, 12.1-81.5+ months). In patients with ongoing response, median TTP was 53.9 months (range, 49-82+ months). Conclusions: 90Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Failure to respond to prior therapy does not preclude achieving a long-term response with 90Y ibritumomab tiuxetan.",
keywords = "Durable responses, Non-Hodgkin's lymphoma, Time to progression, Yttrium-90 ibritumomab tiuxetan",
author = "Wiseman, {Gregory A.} and Witzig, {Thomas Elmer}",
year = "2005",
doi = "10.1089/cbr.2005.20.185",
language = "English (US)",
volume = "20",
pages = "185--188",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

AU - Wiseman, Gregory A.

AU - Witzig, Thomas Elmer

PY - 2005

Y1 - 2005

N2 - Aim: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%. This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with 90Y ibritumomab tiuxetan treatment. Materials and Methods: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed. Time to progression (TTP) of ≥12 months was noted in 78 patients (37%), who were identified as long-term responders and were further characterized. Results: Median age of the long-term responders was 58 years (range, 24-80 years) with 44% over 60 years, and 55% were male. Notably, 59% of patients had received ≥2 prior regimens, 33% had received ≥3 prior regimens, and 37% had failed to respond to immediate prior therapy. Median response duration was 28.1 months (range, 10.5-80.3+ months). Median TTP was 29.3 months (range, 12.1-81.5+ months). In patients with ongoing response, median TTP was 53.9 months (range, 49-82+ months). Conclusions: 90Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Failure to respond to prior therapy does not preclude achieving a long-term response with 90Y ibritumomab tiuxetan.

AB - Aim: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%. This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with 90Y ibritumomab tiuxetan treatment. Materials and Methods: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed. Time to progression (TTP) of ≥12 months was noted in 78 patients (37%), who were identified as long-term responders and were further characterized. Results: Median age of the long-term responders was 58 years (range, 24-80 years) with 44% over 60 years, and 55% were male. Notably, 59% of patients had received ≥2 prior regimens, 33% had received ≥3 prior regimens, and 37% had failed to respond to immediate prior therapy. Median response duration was 28.1 months (range, 10.5-80.3+ months). Median TTP was 29.3 months (range, 12.1-81.5+ months). In patients with ongoing response, median TTP was 53.9 months (range, 49-82+ months). Conclusions: 90Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Failure to respond to prior therapy does not preclude achieving a long-term response with 90Y ibritumomab tiuxetan.

KW - Durable responses

KW - Non-Hodgkin's lymphoma

KW - Time to progression

KW - Yttrium-90 ibritumomab tiuxetan

UR - http://www.scopus.com/inward/record.url?scp=18844435974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844435974&partnerID=8YFLogxK

U2 - 10.1089/cbr.2005.20.185

DO - 10.1089/cbr.2005.20.185

M3 - Article

C2 - 15869453

AN - SCOPUS:18844435974

VL - 20

SP - 185

EP - 188

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 2

ER -